market access

News

Merck & Co signs biosimilars deal for US veterans

Merck & Co has signed a deal with the US Department of Veterans Affairs (VA) for its inflammatory diseases biosimilar, Renflexis, so that veterans’ care can be improved.

News

Madrid, Spain - November 3, 2017: Vintage storefront in Malasaña district in Madrid. Malasaña is one of the trendiest neighborhoods in Madrid, well known for its counter-cultural scene

Digital technology could revolutionise drug reimbursement in...

Digital technology could play a major role in creating a system that reimburses medicines based on their efficacy in Spain, according to the country’s pharma trade body.

News

Patients call for end to CF drug price row at key meeting

Representatives of NHS England and cystic fibrosis drug company Vertex are to meet on Thursday to try and resolve a two-year impasse over access to life-changing medications.

News

Gilead launches generics of own hepatitis C drugs in US to c...

Gilead is to launch cheaper generic versions of its hepatitis C drugs in the US, responding to calls for lower drug prices because of spiralling healthcare costs.

Partner Content

Partner Content

Only 4 Weeks Until Orphan Drugs & Rare Diseases 2018

Pharma Giants Unite to Improve Rare Disease Treatment

News

NICE rejects Novartis' CAR-T in adult lymphoma

NICE has said Novartis’ CAR-T therapy Kymriah cannot be funded by the NHS in adults with an aggressive form of lymphoma, calling for further discussions to get the drug on to the market.

Merck & Co signs biosimilars deal for US veterans

Digital technology could revolutionise drug reimbursement in...

Patients call for end to CF drug price row at key meeting

Gilead launches generics of own hepatitis C drugs in US to c...

Only 4 Weeks Until Orphan Drugs & Rare Diseases 2018

NICE rejects Novartis' CAR-T in adult lymphoma

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

market access

Editor's Picks